Seguimiento de 20 pacientes portadores de fibrosis pulmonar idiopática tratados con nintedanib / Follow-up of 20 patients with idiopathic pulmonary fibrosis treated with nintedanib
Rev. chil. enferm. respir
; 38(3): 160-167, sept. 2022. tab, graf
Article
in Es
| LILACS
| ID: biblio-1423697
Responsible library:
CL126.2
RESUMEN
Se presenta un estudio observacional compasivo de seguimiento de 20 pacientes portadores de Fibrosis Pulmonar Idiopática tratados con Nintedanib, que muestra que Nintedanib es un medicamento en general bien tolerado, sin efectos adversos serios, que otorga una sobrevida más prolongada que la que cabría esperar en pacientes con esta enfermedad.
ABSTRACT
A compassionate observational follow-up study of 20 patients with Idiopathic Pulmonary Fibrosis treated with Nintedanib is presented, showing that Nintedanib is a generally well-tolerated drug, with no serious adverse effects, that grants a longer survival in real-life patients.
Key words
Full text:
1
Index:
LILACS
Main subject:
Protein Kinase Inhibitors
/
Idiopathic Pulmonary Fibrosis
/
Indoles
Type of study:
Observational_studies
/
Prognostic_studies
Limits:
Aged
/
Female
/
Humans
/
Male
Language:
Es
Journal:
Rev. chil. enferm. respir
Journal subject:
PNEUMOLOGIA
Year:
2022
Type:
Article